MedPath

Eli Lilly and Co

🇺🇸United States
Ownership
-
Employees
43K
Market Cap
$859.4B
Website
Introduction

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials
Related News

A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel

Phase 1
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Clopidogrel
Drug: LY2216684
First Posted Date
2010-12-20
Last Posted Date
2018-10-22
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
47
Registration Number
NCT01263093
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States

A Study of LY2216684 and Warfarin in Healthy Subjects

Phase 1
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Warfarin
Drug: LY2216684
First Posted Date
2010-12-20
Last Posted Date
2019-01-22
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
18
Registration Number
NCT01263119
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States

A Phase 1b Trial in Patients With Renal Cell Cancer

Phase 1
Completed
Conditions
Metastatic Renal Cell Cancer
Interventions
Drug: Sunitinib
First Posted Date
2010-12-10
Last Posted Date
2019-01-10
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
21
Registration Number
NCT01258348
Locations
🇨🇦

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada

A Study to Evaluate the Pharmacokinetics of LY2624803 in Subjects With Hepatic Impairment

Phase 1
Terminated
Conditions
Insomnia
Interventions
Drug: LY2624803
First Posted Date
2010-12-09
Last Posted Date
2011-06-03
Lead Sponsor
Eli Lilly and Company
Registration Number
NCT01257178
Locations
🇷🇺

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation

A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer

Phase 1
Completed
Conditions
Breast Cancer
Metastatic Breast Cancer
Interventions
Biological: Ramucirumab
Drug: Docetaxel
First Posted Date
2010-12-08
Last Posted Date
2014-06-18
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
7
Registration Number
NCT01256567
Locations
🇯🇵

ImClone Investigational Site, Osaka, Japan

🇯🇵

Imclone Investigational Site, Nagoya, Japan

A Study for Japanese Participants With Rheumatoid Arthritis (RA)

Phase 1
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Placebo
Drug: LY2127399 (Tabalumab)
First Posted Date
2010-12-03
Last Posted Date
2018-10-23
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
32
Registration Number
NCT01253226
Locations
🇯🇵

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan

A Multiple-Ascending Dose Study in Type 2 Diabetes Mellitus Patients

Phase 1
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: LY2393910
Drug: Placebo
First Posted Date
2010-12-03
Last Posted Date
2011-06-10
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
38
Registration Number
NCT01253278
Locations
🇩🇪

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, Germany

A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment

Phase 1
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: LY2189265
First Posted Date
2010-12-03
Last Posted Date
2014-10-07
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
26
Registration Number
NCT01253304
Locations
🇭🇺

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary

Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas

Phase 1
Completed
Conditions
Adenocarcinoma
Interventions
Biological: Ramucirumab (IMC-1121B )
Drug: Paclitaxel
First Posted Date
2010-12-03
Last Posted Date
2014-06-18
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
6
Registration Number
NCT01253525
Locations
🇯🇵

ImClone Investigational Site, Osaka, Japan

A Study of Japanese Rheumatoid Arthritis Participants

Phase 1
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: LY2127399
First Posted Date
2010-12-03
Last Posted Date
2019-03-01
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
26
Registration Number
NCT01253291
Locations
🇯🇵

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy